Tucatinib Continuation Study
Conditions
- HER2-positive Breast Cancer
- Cervical Cancer
- Biliary Tract Neoplasms
- Urothelial Cancer
- Advanced Non-Small Cell Lung Cancer
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
- Colorectal Cancer
Interventions
Sponsor
Pfizer